AU2010248702A1 - TTK peptides and vaccines including the same - Google Patents

TTK peptides and vaccines including the same Download PDF

Info

Publication number
AU2010248702A1
AU2010248702A1 AU2010248702A AU2010248702A AU2010248702A1 AU 2010248702 A1 AU2010248702 A1 AU 2010248702A1 AU 2010248702 A AU2010248702 A AU 2010248702A AU 2010248702 A AU2010248702 A AU 2010248702A AU 2010248702 A1 AU2010248702 A1 AU 2010248702A1
Authority
AU
Australia
Prior art keywords
peptide
present
cancer
peptides
ttk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010248702A
Other languages
English (en)
Inventor
Yusuke Nakamura
Ryuji Ohsawa
Takuya Tsunoda
Tomohisa Watanabe
Sachiko Yoshimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of AU2010248702A1 publication Critical patent/AU2010248702A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010248702A 2009-05-11 2010-05-10 TTK peptides and vaccines including the same Abandoned AU2010248702A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21601709P 2009-05-11 2009-05-11
US61/216,017 2009-05-11
PCT/JP2010/003166 WO2010131452A1 (en) 2009-05-11 2010-05-10 Ttk peptides and vaccines including the same

Publications (1)

Publication Number Publication Date
AU2010248702A1 true AU2010248702A1 (en) 2011-11-17

Family

ID=43084837

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010248702A Abandoned AU2010248702A1 (en) 2009-05-11 2010-05-10 TTK peptides and vaccines including the same

Country Status (13)

Country Link
US (1) US8530430B2 (enExample)
EP (1) EP2430039A4 (enExample)
JP (1) JP5786178B2 (enExample)
KR (1) KR20120029394A (enExample)
CN (1) CN102459314B (enExample)
AU (1) AU2010248702A1 (enExample)
BR (1) BRPI1013938A2 (enExample)
CA (1) CA2761393A1 (enExample)
MX (1) MX2011012013A (enExample)
RU (1) RU2531348C2 (enExample)
SG (1) SG175998A1 (enExample)
TW (1) TW201102081A (enExample)
WO (1) WO2010131452A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2663350C2 (ru) * 2012-09-11 2018-08-03 Онкотерапи Сайенс, Инк. Пептиды ube2t и содержащие их вакцины
CN110214144B (zh) * 2016-11-16 2023-05-02 深圳华大生命科学研究院 多肽及其应用
CN109952308B (zh) 2016-11-29 2022-09-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
PT3652606T (pt) * 2017-07-12 2023-03-16 Nouscom Ag Vacina universal baseada em neoantigénios tumorais partilhados para prevenção e tratamento de cancros com microssatélites instáveis (msi)
CN120712104A (zh) * 2022-10-14 2025-09-26 广东天科雅生物医药科技有限公司 针对神经胶质瘤的肽疫苗及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187548B1 (en) * 1993-05-23 2001-02-13 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods using human calcium sensor protein, fragments thereof and DNA encoding same
US20030045491A1 (en) 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
CA2438092C (en) 2001-02-21 2011-08-09 Chiron Corporation Ttk in diagnosis and as a therapeutic target in cancer
US7501243B2 (en) * 2001-02-21 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Detection of colon or breast cancer by measuring TTK polypeptide expression
JP2005527180A (ja) 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
AU2003210393A1 (en) * 2002-02-27 2003-09-09 Michael Rik Frans Brands A data integration and knowledge management solution
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
EP1998177A3 (en) 2003-01-06 2009-02-18 Wyeth Compositions and methods for diagnosing and treating colon cancers
US20050266409A1 (en) 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
WO2004094636A1 (en) 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
CA2539651A1 (en) 2003-09-22 2005-04-07 Rosetta Inpharmatics Llc Synthetic lethal screen using rna interference
JP4721903B2 (ja) 2004-01-29 2011-07-13 大日本住友製薬株式会社 新規腫瘍抗原蛋白質及びその利用
GB0426393D0 (en) 2004-12-01 2005-01-05 Cancer Rec Tech Ltd Materials and methods relating to modulators of spindle checkpoint kinases
CA2589918A1 (en) 2004-12-08 2006-06-15 Dorre Grueneberg Method for measuring resistance or sensitivity to docetaxel comprising detection of tacc3
EP2011885B1 (en) 2005-02-10 2015-04-22 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
ES2459492T3 (es) 2005-02-25 2014-05-09 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos TTK, URLC10 o KOC1
WO2007013665A2 (en) 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
CN101273144B (zh) 2005-07-27 2011-12-28 肿瘤疗法科学股份有限公司 诊断食道癌的方法
US20100009920A1 (en) 2006-12-13 2010-01-14 Yusuke Nakamura Ttk as tumor marker and therapeutic target for lung cancer
TWI615403B (zh) 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
WO2009079768A1 (en) 2007-12-21 2009-07-02 University Health Network Methods of inhibiting tumor growth using ttk antagonists
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
KR20120029394A (ko) 2012-03-26
WO2010131452A1 (en) 2010-11-18
RU2531348C2 (ru) 2014-10-20
US20120135020A1 (en) 2012-05-31
EP2430039A4 (en) 2012-12-05
JP5786178B2 (ja) 2015-09-30
RU2011150283A (ru) 2013-06-20
US8530430B2 (en) 2013-09-10
EP2430039A1 (en) 2012-03-21
CN102459314B (zh) 2016-01-20
TW201102081A (en) 2011-01-16
SG175998A1 (en) 2011-12-29
CN102459314A (zh) 2012-05-16
BRPI1013938A2 (pt) 2019-09-24
MX2011012013A (es) 2012-02-23
CA2761393A1 (en) 2010-11-18
JP2012526519A (ja) 2012-11-01

Similar Documents

Publication Publication Date Title
AU2011208271B2 (en) Modified MELK peptides and vaccines containing the same
US20130108664A1 (en) Cdca5 peptides and vaccines including the same
AU2012296090B2 (en) MPHOSPH1 peptides and vaccines including the same
AU2012265677A1 (en) SEMA5B peptides and vaccines including the same
US8530430B2 (en) TTK peptides and vaccines including the same
US20170198010A1 (en) Tomm34 peptides and vaccines including the same
AU2011300253B2 (en) TTLL4 peptides and vaccines containing the same
AU2011233401B2 (en) ECT2 peptides and vaccines including the same
WO2011074236A1 (en) Tmem22 peptides and vaccines including the same
AU2011225577A1 (en) HJURP peptides and vaccines including the same
WO2014087626A1 (en) Sema5b peptides and vaccines containing the same
US20130287805A1 (en) C18orf54 peptides and vaccines including the same
US20130309259A1 (en) Wdhd1 peptides and vaccines including the same
WO2011125139A1 (en) Cluap1 peptides and vaccines including the same
HK1180003B (en) Ect2 peptides and vaccines including the same
HK1180003A (en) Ect2 peptides and vaccines including the same

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application